Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics completes $1.55 billion sale of sevasemten program to Servier

Positive Impact 4 of 5 m&a Written later

Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier on July 10, 2026, receiving $1.55 billion in upfront cash plus up to $1.1 billion in additional milestone payments. The company says the proceeds strengthen its balance sheet and will fully fund development of its cardiovascular pipeline, led by EDG-7500, through potential approval.

Key points

  • Upfront cash consideration of $1.55 billion; milestone payments of up to $1.1 billion, for aggregate potential consideration of up to $2.65 billion.
  • Transaction completed July 10, 2026; Edgewise announced completion in a press release dated July 13, 2026.
  • Edgewise expects to start a Phase 3 trial of EDG-7500 in the fourth quarter of 2026 and a Phase 2 trial of EDG-15400 in HFpEF.
  • Edgewise intends to file pro forma financial information in a Form 8-K/A no later than four business days after completion.

The filing

CompanyEdgewise Therapeutics, Inc. (EWTX)
Form8-K, current report
Filed with the SECJul 13, 2026, 8:37 AM ET
Accession number0001104659-26-082902

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.